PR104
Asset
Hypoxia-activated prodrug converted to a DNA-crosslinking agent
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- DNA damage response
- 1
- Indication
- 555
- Trials
- 1
- Developer
Indications
1Hepatocellular carcinoma
Phase 1, Terminated, NCT00862082, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Trials555
- Evidence for its targets3
- Competitors12
Every asset’s record: target, stage, trials and the evidence behind it.